Sutent Pancreatic Tumor Study Shows Regulatory Pitfalls Of Stopping Early

Pfizer’s development of Sutent (sunitinib) for treatment of pancreatic tumors shows the potential pitfalls sponsors face when they decide to terminate clinical trials early due to positive results.